Marine organisms and other novel natural sources of new cancer drugs

Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

Wani, M. C., Taylor, H. L., Wall, M. E., COGGON, P., & McPhail, A. T. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00738a045 · Cited by 4,083 · see citing works

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke‐Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,798 · see citing works

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata 1,2

Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A., & Sim, G. A. (1966) · Journal of the American Chemical Society · doi:10.1021/ja00968a057 · Cited by 2,262 · see citing works

Natural Products in Drug Discovery and Development

Cragg, G. M. L., Newman, D. J., & Snader, K. M. (1997) · Journal of Natural Products · doi:10.1021/np9604893 · Cited by 1,589 · see citing works

Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease

DeVita, V. T., SERPICK, A. A., & CARBONE, P. P. (1970) · Annals of Internal Medicine · doi:10.7326/0003-4819-73-6-881 · Cited by 1,445 · see citing works

Medicinal plants in therapy

Farnsworth, N. R., Akerele, O., & Bingel, A. S. (1987) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(87)90016-x · Cited by 1,365 · see citing works

Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or Etoposide

Williams, S. D., Birch, R., Einhorn, L. H., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162302 · Cited by 1,181 · see citing works

Cancer principles and practice of oncology

Kerin, M. J. (1997) · Surgical Oncology · doi:10.1016/s0960-7404(97)90012-8 · Cited by 744 · see citing works

Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.

Bollag, D. M., McQueney, P. A., Zhu, J., Hensens, O. D., Koupal, L. R., Liesch, J. M., Goetz, M., Lazarides, E., & Woods, C. M. (1995) · PubMed · Cited by 687 · see citing works

The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10

Pettit, G. R., Kamano, Y., Herald, C. L., Tuinman, A. A., Boettner, F. E., Kizu, H., Schmidt, J. M., Baczynskyj, L., Tomer, K. B., & Bontems, R. J. (1987) · Journal of the American Chemical Society · doi:10.1021/ja00256a070 · Cited by 583 · see citing works

THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS.

JOHNSON, I. S., Jg, A., Gorman, M., & Jp, B. (1963) · PubMed · Cited by 564 · see citing works

Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

Carlson, B. A., Dubay, M., Sausville, E. A., Brizuela, L., & Worland, P. J. (1996) · PubMed · Cited by 530 · see citing works

FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor

Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M., & Horinouchi, S. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4027 · Cited by 484 · see citing works

Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.

Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., YOKOKURA, T., Sawada, S., Miyasaka, T., & Mutai, M. (1987) · PubMed · Cited by 410 · see citing works

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

Senderowicz, A. M., Headlee, D. J., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L., Hill, K. D., Steinberg, S. M., Figg, W. D., Tompkins, A. C., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2986 · Cited by 404 · see citing works

Untitled work

Bergmann (1951) · doi:10.1021/jo01146a023 · Cited by 403 · see citing works

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

Creemers, G. J., Bolis, G., Gore, M. E., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.12.3056 · Cited by 386 · see citing works

Discodermolide, A Cytotoxic Marine Agent That Stabilizes Microtubules More Potently Than Taxol^,

ter Haar, E., Kowalski, R. J., Hamel, E., Lin, C. M., Longley, R. E., Gunasekera, S. P., Rosenkranz, H. S., & Day, B. W. (1996) · Biochemistry · doi:10.1021/bi9515127 · Cited by 382 · see citing works

Plants Used against Cancer

Forero, E., & Hartwell, J. L. (1989) · The Bryologist · doi:10.2307/3244038 · Cited by 376 · see citing works

Rapamycin Inhibition of the G1 to S Transition Is Mediated by Effects on Cyclin D1 mRNA and Protein Stability

Hashemolhosseini, S., Nagamine, Y., Morley, S., Desrivières, S., Merćep, L., & Ferrari, S. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14424 · Cited by 343 · see citing works

Dolastatin 10, a powerful cytostatic peptide derived from a marine animal

Bai, R., Petit, G. R., & Hamel, E. (1990) · Biochemical Pharmacology · doi:10.1016/0006-2952(90)90613-p · Cited by 321 · see citing works

Rational design of aromatic polyketide natural products by recombinant assembly of enzymatic subunits

McDaniel, R. N., Ebert‐Khosla, S., Hopwood, D. A., & Khosla, C. (1995) · Nature · doi:10.1038/375549a0 · Cited by 283 · see citing works

The Microtubule-Stabilizing Agent Discodermolide Competitively Inhibits the Binding of Paclitaxel (Taxol) to Tubulin Polymers, Enhances Tubulin Nucleation Reactions More Potently than Paclitaxel, and Inhibits the Growth of Paclitaxel-Resistant Cells

Kowalski, R. J., Giannakakou, P., Gunasekera, S. P., Longley, R. E., Day, B. W., & Hamel, E. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.4.613 · Cited by 262 · see citing works

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.

Pitot, H. C., Wender, D. B., O’Connell, M. J., Schroeder, G. S., Goldberg, R. M., Rubin, J., Mailliard, J. A., Knost, J. A., Ghosh, C., Kirschling, R. J., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2910 · Cited by 259 · see citing works

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.

Ueda, H., Manda, T., Matsumoto, S., Mukumoto, S., Nishigaki, F., Kawamura, I., & Shimomura, K. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.315 · Cited by 258 · see citing works

Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.

Marco, A. D., Gaetani, M., & Scarpinato, B. (1969) · PubMed · Cited by 243 · see citing works

Ecteinascidin 743: A Minor Groove Alkylator That Bends DNA toward the Major Groove

Zewail‐Foote, M., & Hurley, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990241l · Cited by 215 · see citing works

The Role of Ethnopharmacology in Drug Development

Farnsworth, N. R. (2007) · Novartis Foundation symposium · doi:10.1002/9780470514009.ch2 · Cited by 208 · see citing works

The bioprocess–technological potential of the sea

Pomponi, S. A. (1999) · Journal of Biotechnology · doi:10.1016/s0168-1656(99)00053-x · Cited by 164 · see citing works

A phase I study of intravenous bryostatin 1 in patients with advanced cancer

Prendiville, J., Crowther, D., Thatcher, N., Woll, P. J., Fox, B. W., McGown, A. T., Testa, N. G., Stern, P. L., McDermott, R. H., Potter, M., et al. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.352 · Cited by 145 · see citing works

Discovery and Development of Antineoplastic Agents from Natural Sources

Suffness, M., Newman, D. J., & Snader, K. M. (1989) · Bioorganic marine chemistry · doi:10.1007/978-3-642-74560-7_6 · Cited by 145 · see citing works

Action of FR901228, a Novel Antitumor Bicyclic Depsipeptide Produced byChromo-bacterium violaceumNo. 968, on Ha-rasTransformed NIH3T3 Cells

Ueda, H., Nakajima, H., Hori, Y., et al. (1994) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.58.1579 · Cited by 144 · see citing works

Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.

Hornung, R. L., Pearson, J. W., Beckwith, M., & Longo, D. L. (1992) · PubMed · Cited by 134 · see citing works

Untitled work

(1997) · PubMed · Cited by 134 · see citing works

The Ethnobotanical Approach to Drug Discovery: Strengths and Limitations

Cox, P. A. (2007) · Novartis Foundation symposium · doi:10.1002/9780470514634.ch3 · Cited by 132 · see citing works

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion

Jayson, G. C., Crowther, D., Prendiville, J., McGown, A. T., Scheid, C., Stern, P. L., Young, R., Brenchley, P. E., Chang, J., Owens, S. E., et al. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.356 · Cited by 125 · see citing works

Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Varterasian, M. L., Mohammad, R. M., Eilender, D., Hulburd, K., Rodriguez, D. H., Pemberton, P. A., Pluda, J. M., Dan, M., Pettit, G. R., Chen, B. D. M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.56 · Cited by 114 · see citing works

Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.

MacDonald, J. R., Muscoplat, C. C., Dexter, D. L., et al. (1997) · PubMed · Cited by 109 · see citing works

Essential drugs for cancer therapy: A World Health Organization consultation

Sikora, K., Advani, S., Koroltchouk, V., Magrath, I. T., Lévy, L., Pinedo, H. M., Schwartsmann, G., Tattersall, M., & Yan, S. (1999) · Annals of Oncology · doi:10.1023/a:1008367822016 · Cited by 106 · see citing works

High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer

Hendriks, H. R., Fiebig, H. H., Giavazzi, R., et al. (1999) · Annals of Oncology · doi:10.1023/a:1008364727071 · Cited by 103 · see citing works

Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114)

WOYNAROWSKI, J. M., Napier, C., Koester, S. K., et al. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00321-3 · Cited by 100 · see citing works

Immunomodulatory and Anti-Tumour Polysaccharides from Medicinal Plants

Wong, C. K., Leung, K. N., Fung, K., et al. (1994) · Journal of International Medical Research · doi:10.1177/030006059402200601 · Cited by 99 · see citing works

Didemnin B

Chun, H. G., Davies, B., Hoth, D. F., et al. (1986) · Investigational New Drugs · doi:10.1007/bf00179597 · Cited by 96 · see citing works

Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.

Madden, T. L., Tran, H. T., Beck, D., et al. (2000) · PubMed · Cited by 90 · see citing works

Discovery and Development of Antineoplastic Agents from Natural Sources

Cragg, G. M. L., & Newman, D. J. (1999) · Cancer Investigation · doi:10.1080/07357909909011730 · Cited by 88 · see citing works

Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins.

Trenn, G., Pettit, G. R., Takayama, H., Hu‐Li, J., & Sitkovsky, M. V. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.2.433 · Cited by 78 · see citing works

PLANT-DERIVED NATURAL PRODUCTS IN DRUG DISCOVERY AND DEVELOPMENT: AN OVERVIEW

Bahar, M., Deng, Y., Fletcher, J. N., et al. (2007) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789812790781_0002 · Cited by 76 · see citing works

Ciba Foundation Symposium 185 ‐ Ethnobotany and the Search for New Drugs

(2007) · Novartis Foundation symposium · doi:10.1002/9780470514634 · Cited by 75 · see citing works

Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1.

Basu, A., & Lazo, J. S. (1992) · PubMed · Cited by 74 · see citing works

Phase-trafficking reagents and phase-switching strategies for parallel synthesis

Flynn, D. L. (1999) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199909)19:5 · Cited by 61 · see citing works

Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.

Christian, M. C., Pluda, J. M., Ho, P. T. C., et al. (1997) · PubMed · Cited by 57 · see citing works

Amazonian Ethnobotany and the Search for New Drugs

Schultes, R. E. (2007) · Novartis Foundation symposium · doi:10.1002/9780470514634.ch8 · Cited by 55 · see citing works

Clinical highlights from the National Cancer Data Base: 1996

Jessup, J. M., McGinnis, L. S., Winchester, D. P., et al. (1996) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.46.3.185 · Cited by 46 · see citing works

Dolastatin-10 induces polyploidy, telomeric associations and apoptosis in a murine melanoma cell line.

Pathak, S., Multani, A. S., Ozen, M., Richardson, M. A., & Newman, R. A. (1998) · Oncology Reports · doi:10.3892/or.5.2.373 · Cited by 32 · see citing works

Summary of the Workshop on Drug Development, Biological Diversity, and Economic Growth

Schweitzer, J., Handley, F. G., Edwards, J. D., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.18.1294 · Cited by 32 · see citing works

A phase II trial of didemnin B in myeloma

Weiss, R. B., Peterson, B. L., Allen, S. L., et al. (1994) · Investigational New Drugs · doi:10.1007/bf00873234 · Cited by 27 · see citing works

The National Cooperative Natural Products Drug Discovery Group (NCNPDDG) and International Cooperative Biodiversity Group (ICBG) Programs

Suffness, M., Cragg, G., Grever, M. M., et al. (1995) · Pharmaceutical Biology · doi:10.3109/13880209509067083 · Cited by 21 · see citing works

Effect of dolastatin 10 on human non-Hodgkinʼs lymphoma cell lines

Maki, A., Mohammad, R., Raza, S., Saleh, M., Govindaraju, K., Pettit, G. R., & Al-Katib, A. M. (1996) · Anti-Cancer Drugs · doi:10.1097/00001813-199605000-00016 · Cited by 20 · see citing works

Synthesis and cytostatic activities of didemnin derivatives*

Schmidt, U., Grießer, H., Haas, G. R., et al. (1999) · Journal of Peptide Research · doi:10.1034/j.1399-3011.1999.00097.x · Cited by 17 · see citing works

Anticancer Drugs: Antimetabolite Metabolism and Natural Anticancer Agents

Powis, G. (1994) · Medical Entomology and Zoology · Cited by 14 · see citing works

[Rapamycin and CCI-779].

Alexandre, J., Raymond, É., & Armand, J. (1999) · PubMed · Cited by 14 · see citing works

Irinotecan for colorectal cancer

Pozzo, C., Cassano, A., & Barone, C. (1998) · PharmacoEconomics & Outcomes News · doi:10.1007/bf03273532 · Cited by 14 · see citing works

Anti-tumor Marine Natural Products.

Kitagawa, I., & Kobayashi, M. (1991) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.49.1053 · Cited by 11 · see citing works

Modulation of cIAP-1 by Novel Antitubulin Agents When Combined with Bryostatin 1 Results in Increased Apoptosis in the Human Early Pre-B Acute Lymphoblastic Leukemia Cell Line Reh

Wall, N. R., Mohammad, R. M., Nabha, S. M., Pettit, G. R., & Al-Katib, A. M. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1768 · Cited by 10 · see citing works

Recent progress in the study of anticancer drugs originating from plants and traditional medicines in China.

Han, R. (1994) · PubMed · Cited by 8 · see citing works

RECENT PROGRESS IN THE STUDY OF ANTICANCER DRUGS ORIGINATING FROM PLANTS AND TRADITIONAL MEDICINES IN CHINA

韩锐 (1994) · 中国医学科学杂志：英文版 · Cited by 5 · see citing works

ChemInform Abstract: Antitumor Marine Natural Products

Kitagawa, I., & Kobayashi, M. (1992) · ChemInform · doi:10.1002/chin.199218336 · Cited by 4 · see citing works

Untitled work

Rinehart (2000) · doi:10.1002/(sici)1098-1128(200001)20:1

Marine Natural Products: A Source of Novel Anticancer Drugs

Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555 · see citing works

Marine organisms as a source of new anticancer agents

Schwartsmann, G., da Rocha, A. B., Berlinck, R. G., & Jimeno, J. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00292-8 · Cited by 261 · see citing works

Realizing the promises of marine biotechnology

Luiten, E. E. M., Akkerman, I., Koulman, A., Kamermans, P., Reith, H., Barbosa, M. J., Sipkema, D., & Wijffels, R. H. (2003) · Biomolecular Engineering · doi:10.1016/s1389-0344(03)00074-1 · Cited by 66 · see citing works

Susquehanna Chorale Spring Concert "Roots and Wings"

Hawkins, D. (2017)

Genentech taps Affimed’s antibodies

Cross, R. (2018) · C&EN Global Enterprise · doi:10.1021/cen-09635-buscon15

KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIK

Sari, D. (2023) · Jurnal Komplikasi Anestesi · doi:10.22146/jka.v5i1.7322

Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoria

Dib, A., Puig, L. B., Salvadori, D., et al. (1988) · Arquivos Brasileiros de Cardiologia

Interleucinas na encefalopatia hipóxico-isquêmica

Ceccon, M. E. J. R. (2003) · Jornal de Pediatria · doi:10.1590/s0021-75572003000400002 · Cited by 14 · see citing works